Who
Luis C. Pena
President & CEO
Company insider
Files Form 4 as: President & CEO, Evommune; Chief Development Officer, Dermira.
In numbers
- Trades disclosed
- 80
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $1.9M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 2 Oct 2014
- Last trade
- 30 Sep 2026
- Last filed
- 15 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 15 Oct 2026 | EVMN EvommuneBiotechnology | SEC FORM 4 Code A | $7,8271,115 at $7.02 | filing |
| 22 Jun 2026filed 24 Jun 2026 | EVMN EvommuneBiotechnology | SEC FORM 4 Sold | $169K7,438 at $22.71 | filing |
| 22 Jun 2026filed 24 Jun 2026 | EVMN EvommuneBiotechnology | SEC FORM 4 Sold | $169K7,438 at $22.71 | filing |
| 1 Jun 2026filed 3 Jun 2026 | EVMN EvommuneBiotechnology | SEC FORM 4 Sold | $382K16,787 at $22.74 | filing |
| 1 Jun 2026filed 3 Jun 2026 | EVMN EvommuneBiotechnology | SEC FORM 4 Sold | $382K16,787 at $22.74 | filing |
| 16 Apr 2026filed 17 Apr 2026 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —291,420 at $0.00 | filing |
| 16 Apr 2026filed 17 Apr 2026 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —291,420 at $0.00 | filing |
| 9 Dec 2025filed 11 Dec 2025 | EVMN EvommuneBiotechnology | SEC FORM 4 Code F | $502K28,138 at $17.84 | filing |
| 7 Nov 2025filed 12 Nov 2025 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code C | —206,355 | filing |
| 7 Nov 2025filed 12 Nov 2025 | EVMN EvommuneBiotechnology | SEC FORM 4 Code C | —24,225 | filing |
| 5 Nov 2025filed 7 Nov 2025 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —796,841 at $0.00 | filing |
| 20 Feb 2020filed 24 Feb 2020 | Dermiraoption or derivative | SEC FORM 4 Code D | —88,251 | filing |
| 20 Feb 2020filed 24 Feb 2020 | Dermiraoption or derivative | SEC FORM 4 Code D | —32,506 | filing |
| 20 Feb 2020filed 24 Feb 2020 | Dermiraoption or derivative | SEC FORM 4 Code D | —71,397 | filing |
| 20 Feb 2020filed 24 Feb 2020 | Dermiraoption or derivative | SEC FORM 4 Code D | —17,062 | filing |
| 20 Feb 2020filed 24 Feb 2020 | Dermiraoption or derivative | SEC FORM 4 Code D | —50,178 | filing |
| 20 Feb 2020filed 24 Feb 2020 | Dermiraoption or derivative | SEC FORM 4 Code D | —60,000 | filing |
| 20 Feb 2020filed 24 Feb 2020 | Dermiraoption or derivative | SEC FORM 4 Code D | —10,000 | filing |
| 20 Feb 2020filed 24 Feb 2020 | Dermiraoption or derivative | SEC FORM 4 Code D | —48,750 | filing |
| 20 Feb 2020filed 24 Feb 2020 | Dermiraoption or derivative | SEC FORM 4 Code D | —63,750 | filing |
News
Evommune (NYSE:EVMN) Stock Bumped Up to "Hold" by UBS GroupEVMN · tickerreport.com · 14 Oct 2026Evommune (NYSE:EVMN) Upgraded at UBS GroupEVMN · dailypolitical.com · 14 Oct 2026
0 headlines in the last 90 days name Luis C. Pena; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.